We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode (APPRAISE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04203056
Recruitment Status : Terminated (Withdraw of financial support by industry collaborator)
First Posted : December 18, 2019
Last Update Posted : October 12, 2022
Alkermes, Inc.
Information provided by (Responsible Party):
Kenneth L. Subotnik, PhD, University of California, Los Angeles

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : October 1, 2022
Actual Study Completion Date : October 1, 2022